FierceBiotech Apr 23, 2026 Despite data concerns, Roche’s oral SERD can still be largest product in company history: exec
BioPharma Dive Apr 23, 2026 Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
Roche Media Apr 23, 2026 Roche Q1 earnings suffer blood bath, but currency headwinds aren’t the only culprit - Fierce Pharma
FierceBiotech Apr 23, 2026 From debt to ‘acceptable’ prices: Roche CEO lists 3 reasons for sitting out Big Pharma M&A spree
Roche Media Apr 23, 2026 From debt to ‘acceptable’ prices: Roche CEO lists 3 reasons for sitting out Big Pharma M&A spree - Fierce Biotech
Roche Media Apr 22, 2026 The latest biotech news: RevMed, Roche, Kyverna CAR-T therapy - statnews.com
FierceBiotech Apr 22, 2026 Roche unpacks death imbalance, secondary endpoints in phase 3 multiple sclerosis trials
Roche Media Apr 21, 2026 With successful trials, Roche takes its MS drug to regulators, but safety questions loom - statnews.com
Roche Media Apr 21, 2026 Roche unpacks death imbalance, secondary endpoints in phase 3 multiple sclerosis trials - Fierce Biotech
FierceBiotech Apr 20, 2026 AACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugs
Roche Media Apr 17, 2026 Roche builds MRD testing arsenal in $595m Saga Diagnostics buyout - Medical Device Network
Roche Media Apr 17, 2026 Roche affiliate to acquire Triangle diagnostics firm for up to $595M - The Business Journals
Roche Media Apr 16, 2026 Roche to launch another Elevidys trial, with eyes on European approval - statnews.com
Roche Media Apr 15, 2026 Could Roche’s Top-Selling Drug Be Harming Women with Primary Progressive Multiple Sclerosis? - Bioengineer.org
Endpoints News Apr 9, 2026 Roche dips into DACs with existing partner C4 Therapeutics for $20M upfront
FierceBiotech Apr 9, 2026 Roche takes 'leap of faith' with $20M bet on C4T’s antibody-targeted protein degraders